Exact Mass: 455.2705
Exact Mass Matches: 455.2705
Found 430 metabolites which its exact mass value is equals to given mass value 455.2705
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
20-Hydroxy-leukotriene E4
20-Hydroxy-leukotriene E4 is a metabolite that can originate from the lipid oxidation of leukotriene E4 (LTE4). LTE4 is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4 activates contractile and inflammatory processes via specific interactions with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways.
Lacidipine
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Erythroskyrin
Erythroskyrin is a mycotoxin produced by the common food storage mould Penicillium islandicu
Lacidipine
2,6-dimethyl-4-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
(13R)-11alpha-acetoxy-2alpha-hydroxy-13-(R-2-methylbutyryloxy)hetisane|trichodelphinine C
(2S,3R,4R,4aS,4bR,6aS,12bS,12cS,14aS)-4a-demethylpaspaline-3,4,4a-triol
3-[11-(3-Hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidin-2,4-dion|3-[11-(3-hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidine-2,4-dione
Ala His Thr Lys
1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methylisoquinolinyl-8,12dihydro-5,6-epoxy-2-hydroxyalantolactone
Ala His Lys Thr
Ala Ile Pro Arg
Ala Ile Arg Pro
Ala Lys His Thr
Ala Lys Thr His
Ala Leu Pro Arg
Ala Leu Arg Pro
Ala Pro Ile Arg
Ala Pro Leu Arg
Ala Pro Arg Ile
Ala Pro Arg Leu
Ala Arg Ile Pro
Ala Arg Leu Pro
Ala Arg Pro Ile
Ala Arg Pro Leu
Ala Thr His Lys
Ala Thr Lys His
Asp Lys Pro Pro
Asp Pro Lys Pro
Asp Pro Pro Lys
Gly His Arg Ser
Gly His Ser Arg
Gly Arg His Ser
Gly Arg Ser His
Gly Ser His Arg
Gly Ser Arg His
His Ala Lys Thr
His Ala Thr Lys
His Gly Arg Ser
His Gly Ser Arg
His Lys Ala Thr
His Lys Thr Ala
His Arg Gly Ser
His Arg Ser Gly
His Ser Gly Arg
His Ser Arg Gly
His Thr Ala Lys
His Thr Lys Ala
Ile Ala Pro Arg
Ile Ala Arg Pro
Ile Ile Asn Pro
Ile Ile Pro Asn
Ile Lys Pro Val
Ile Lys Val Pro
Ile Leu Asn Pro
Ile Leu Pro Asn
Ile Asn Ile Pro
Ile Asn Leu Pro
Ile Asn Pro Ile
Ile Asn Pro Leu
Ile Pro Ala Arg
Ile Pro Ile Asn
Ile Pro Lys Val
Ile Pro Leu Asn
Ile Pro Asn Ile
Ile Pro Asn Leu
Ile Pro Gln Val
Ile Pro Arg Ala
Ile Pro Val Lys
Ile Pro Val Gln
Ile Gln Pro Val
Ile Gln Val Pro
Ile Arg Ala Pro
Ile Arg Pro Ala
Ile Val Lys Pro
Ile Val Pro Lys
Ile Val Pro Gln
Ile Val Gln Pro
Lys Ala His Thr
Lys Ala Thr His
Lys Asp Pro Pro
Lys His Ala Thr
Lys His Thr Ala
Lys Ile Pro Val
Lys Ile Val Pro
Lys Leu Pro Val
Lys Leu Val Pro
Lys Pro Asp Pro
Lys Pro Ile Val
Lys Pro Leu Val
Lys Pro Pro Asp
Lys Pro Val Ile
Lys Pro Val Leu
Lys Thr Ala His
Lys Thr His Ala
Lys Val Ile Pro
Lys Val Leu Pro
Lys Val Pro Ile
Lys Val Pro Leu
Leu Ala Pro Arg
Leu Ala Arg Pro
Leu Ile Asn Pro
Leu Ile Pro Asn
Leu Lys Pro Val
Leu Lys Val Pro
Leu Leu Asn Pro
Leu Leu Pro Asn
Leu Asn Ile Pro
Leu Asn Leu Pro
Leu Asn Pro Ile
Leu Asn Pro Leu
Leu Pro Ala Arg
Leu Pro Ile Asn
Leu Pro Lys Val
Leu Pro Leu Asn
Leu Pro Asn Ile
Leu Pro Asn Leu
Leu Pro Gln Val
Leu Pro Arg Ala
Leu Pro Val Lys
Leu Pro Val Gln
Leu Gln Pro Val
Leu Gln Val Pro
Leu Arg Ala Pro
Leu Arg Pro Ala
Leu Val Lys Pro
Leu Val Pro Lys
Leu Val Pro Gln
Leu Val Gln Pro
Asn Ile Ile Pro
Asn Ile Leu Pro
Asn Ile Pro Ile
Asn Ile Pro Leu
Asn Leu Ile Pro
Asn Leu Leu Pro
Asn Leu Pro Ile
Asn Leu Pro Leu
Asn Pro Ile Ile
Asn Pro Ile Leu
Asn Pro Leu Ile
Asn Pro Leu Leu
Pro Ala Ile Arg
Pro Ala Leu Arg
Pro Ala Arg Ile
Pro Ala Arg Leu
Pro Asp Lys Pro
Pro Asp Pro Lys
Pro Ile Ala Arg
Pro Ile Ile Asn
Pro Ile Lys Val
Pro Ile Leu Asn
Pro Ile Asn Ile
Pro Ile Asn Leu
Pro Ile Gln Val
Pro Ile Arg Ala
Pro Ile Val Lys
Pro Ile Val Gln
Pro Lys Asp Pro
Pro Lys Ile Val
Pro Lys Leu Val
Pro Lys Pro Asp
Pro Lys Val Ile
Pro Lys Val Leu
Pro Leu Ala Arg
Pro Leu Ile Asn
Pro Leu Lys Val
Pro Leu Leu Asn
Pro Leu Asn Ile
Pro Leu Asn Leu
Pro Leu Gln Val
Pro Leu Arg Ala
Pro Leu Val Lys
Pro Leu Val Gln
Pro Asn Ile Ile
Pro Asn Ile Leu
Pro Asn Leu Ile
Pro Asn Leu Leu
Pro Pro Asp Lys
Pro Pro Lys Asp
Pro Pro Arg Ser
Pro Pro Ser Arg
Pro Gln Ile Val
Pro Gln Leu Val
Pro Gln Val Ile
Pro Gln Val Leu
Pro Arg Ala Ile
Pro Arg Ala Leu
Pro Arg Ile Ala
Pro Arg Leu Ala
Pro Arg Pro Ser
Pro Arg Ser Pro
Pro Ser Pro Arg
Pro Ser Arg Pro
Pro Val Ile Lys
Pro Val Ile Gln
Pro Val Lys Ile
Pro Val Lys Leu
Pro Val Leu Lys
Pro Val Leu Gln
Pro Val Gln Ile
Pro Val Gln Leu
Gln Ile Pro Val
Gln Ile Val Pro
Gln Leu Pro Val
Gln Leu Val Pro
Gln Pro Ile Val
Gln Pro Leu Val
Gln Pro Val Ile
Gln Pro Val Leu
Gln Val Ile Pro
Gln Val Leu Pro
Gln Val Pro Ile
Gln Val Pro Leu
Arg Ala Ile Pro
Arg Ala Leu Pro
Arg Ala Pro Ile
Arg Ala Pro Leu
Arg Gly His Ser
Arg Gly Ser His
Arg His Gly Ser
Arg His Ser Gly
Arg Ile Ala Pro
Arg Ile Pro Ala
Arg Leu Ala Pro
Arg Leu Pro Ala
Arg Pro Ala Ile
Arg Pro Ala Leu
Arg Pro Ile Ala
Arg Pro Leu Ala
Arg Pro Pro Ser
Arg Pro Ser Pro
Arg Ser Gly His
Arg Ser His Gly
Arg Ser Pro Pro
Ser Gly His Arg
Ser Gly Arg His
Ser His Gly Arg
Ser His Arg Gly
Ser Pro Pro Arg
Ser Pro Arg Pro
Ser Arg Gly His
Ser Arg His Gly
Ser Arg Pro Pro
Thr Ala His Lys
Thr Ala Lys His
Thr His Ala Lys
Thr His Lys Ala
Thr Lys Ala His
Thr Lys His Ala
Val Ile Lys Pro
Val Ile Pro Lys
Val Ile Pro Gln
Val Ile Gln Pro
Val Lys Ile Pro
Val Lys Leu Pro
Val Lys Pro Ile
Val Lys Pro Leu
Val Leu Lys Pro
Val Leu Pro Lys
Val Leu Pro Gln
Val Leu Gln Pro
Val Pro Ile Lys
Val Pro Ile Gln
Val Pro Lys Ile
Val Pro Lys Leu
Val Pro Leu Lys
Val Pro Leu Gln
Val Pro Gln Ile
Val Pro Gln Leu
Val Gln Ile Pro
Val Gln Leu Pro
Val Gln Pro Ile
Val Gln Pro Leu
Erythroskyrin
20-Hydroxy-leukotriene E4
2-[3-[Bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-methoxybenzene fumarate
2-Methoxy-5-methyl-N,N-bis(1-methylethyl)-3-phenylbenzenepropanaminefumarate
1-[2-[4-(2,2-Dimethyl-7-methoxy-3-phenyl-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine
disodium N-(2-carboxylatoethyl)-N-9-octadecenyl-beta-alaninate
4-[3-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-3-hydroxypropyl]phenol
Felcisetrag
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Felcisetrag (TD-8954) is an orally active, potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Felcisetrag has high affinity (pKi =9.4) for human 5-HT4(c) receptors.
Ibuprofen aluminum
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
Ro 25-6981 maleate
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD)[1][2][3].
D-Erythro-pentitol, 1,5-anhydro-2,3-dideoxy-3-(((1R,3S)-3-((7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl)carbonyl)-3-(1-methylethyl)cyclopentyl)amino)-4-o-methyl-
[Amino-[7-[[6-(1-ethanimidoylpiperidin-4-yl)oxy-2-methylbenzimidazol-1-yl]methyl]naphthalen-2-yl]methylidene]azanium
1-Tetradecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)(1-)
6-({2-[(1,2-Diphenylhydrazinyl)carbonyl]-2-hydroxyhexanoyl}amino)hexanoic acid
4-[[[[8-[(1-Tert-butyl-5-tetrazolyl)methyl]-8-azabicyclo[3.2.1]octan-3-yl]amino]-oxomethyl]amino]benzoic acid ethyl ester
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
4-[4-[(1R,5S)-3-(1,3-benzodioxol-5-ylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyrimidin-5-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
3-methoxy-N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
3-methoxy-N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
3-methoxy-N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
3-methoxy-N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N,N-dimethyl-4-[3-[(E)-prop-1-enyl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
N-[(E)-(2,3-diethoxyphenyl)methylideneamino]-N-(2-hydroxyphenyl)octanediamide
3-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-methoxy-N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(5-pyrimidinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
3-methoxy-N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
(2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
3-[4-[(8R,9S,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8S,9S,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
(2S,3S)-8-(1-cyclohexenyl)-2-[[cyclopentylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
3-methoxy-N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
3-methoxy-N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
2-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
4-methoxy-N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-(propan-2-ylamino)methyl]amino]-2-oxanyl]-N-[(4-phenoxyphenyl)methyl]acetamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-5-[(E)-2-phenylethenyl]-N-[(1S)-1-phenylethyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
(2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-N-(4-phenylphenyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
3-[4-[(8S,9R,10R)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8S,9S,10R)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
3-[4-[(8R,9R,10S)-6-[(2-fluorophenyl)methyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]benzonitrile
2-cyclopropyl-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(4-methylpent-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
3-[4-[(1S,5R)-6-(1,3-benzodioxol-5-ylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
[(2S)-2,3-dihydroxypropyl] [(2S)-2-hydroxy-3-tetradecanoyloxypropyl] phosphate
diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-3,4-dihydropyridine-3,5-dicarboxylate
[(5E)-5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(1H-pyridin-4-ylidene)-1H-imidazol-4-ylidene]-2,3-dihydroinden-1-yl]-oxidoazanium
2-Amino-3-[hydroxy-(2-hydroxy-3-tridecanoyloxypropoxy)phosphoryl]oxypropanoic acid
(1R,3S,4R,5S,8R,10R,14S)-5-[[(1S)-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]methyl]-10,14-dimethyl-2,7-dioxatetracyclo[8.4.0.01,3.04,8]tetradecan-6-one
1-(2-methoxy-13-methyl-tetradecanyl)-sn-glycero-3-phosphoethanolamine
CMF019
CMF019 is a potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents[1]. Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin[2].
Diprotin A (TFA)
Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV)[1].